Pfizer Reports real-world evidence Data for Evolocumab in Renal cell carcinoma

Pfizer today announced real-world evidence results for evolocumab in patients with renal cell carcinoma. The study demonstrated that evolocumab reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of renal cell carcinoma and support the continued development of evolocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.